of P e d i a t r i c s , Honolulu, HI. Peak gentamicin serum concentrations (GSC) of 4-12 mcg/ml and trough concentrations C 2 mcg/ml a r e recommended f o r e f f e c t i v e therapy without t o x i c i t y . Currently recommended gentamicin dosage regimens f o r premature neonates w i t h i n t h e f i r s t week of l i f e have a s i g n i f i c a n t incidence of t o x i c o r subtherapeutic GSC. I n a previous study by t h e a u t h o r s using a standard regimen with f i x e d D I , a n i n v e r s e l i n e a r c o r r e l a t i o n was found between peak and trough GSC and GA. A new gentamicin dosage regimen was formulated based on t h i s c o r r e l a t i o n using a one-compartment pharmacokinetic model. This regimen c o n s i s t s of a 3.5 mq/kg dose given a t a D I which i s i n v e r s e l y r e l a t e d t o GA: D I = 50.5 -0.76 GA. This r e q imen i s designed t o y i e l d peak and trough GSC of 8.0 mcg/rnl and 1.5 mcg/ml, r e s p e c t i v e l y , i n premature i n f a n t s , i r r e s p e c t i v e of GA. To t e s t t h i s new regimen, 32 premature neonates were s t u d i e d within t h e f i r s t week of l i f e . Mean G A was 31.4 weeks (range 25-36); mean b i r t h weight was 1675 grams (range 570-2900). Mean peak and trough GSC (5 SD) were 7.0 + 1.17 mcg/ml and 1.1+ 0.26 mcg/ml, r e s p e c t i v e l y . A l l GSC were w i t h i n t h e recommended range. This i s t h e lowest incidence of inappropriate GSC i n any s e r i e s reported i n t h e l i t e r a t u r e . S e r i a l peak and trough GSC d i d n o t vary s i g n i f i c a n t l y i n i n d i v i d u a l p a t i e n t s during t h e f i r s t 4 days of therapy. The previously observed c o r r e l a t i o n between GSC and G A was l o s t w i t h t h i s regimen. We conclude t h a t r e l a t i n g D I t o GA i n t h i s fashion i s a simple and e f f e c t i v e way of achieving o p t imal peak and trough GSC i n premature i n f a n t s of v a r i o u s GAS. Toxicity t o neonates from drug s o l v e n t s is of concern. We reported serum hyperosmolarity due t o Propylene Glycol (PG) i n MVI-12. This study compared two groups of i n f a n t s weighing <I500 grams. G r PG-received MVI-Conc. Naltrexone is a long-acting analogue of Naloxone w i t h 17x g r e a t e r o p i a t e a n t a g o n i s t a c t i v i t y . (Time t o peak, post i.v. admin. = 1-2h.T1/2=10h i n a d u l t s ) . Animal s t u d i e s , and one study i n prematures, suggest t h a t opioid a n t a g o n i s t s r e v e r s e apnea of prematurity v i a antagonism of B-endorphins (B-ED) . Our study i n f a n t s weighed( 1,700 gms (Gest. age (GA) 28-35 wks) & had s i g n i f i c a n t apnea. (Min. 10/day. Duration 15 sec andfor HRL100 /min andlor cyanosis). 5 i n f a n t s had not received methylxanthines (Group A). 11 i n f a n t s were r e c e i v i n g methylxanthines (Gr. B). EKG, c h e s t w a l l movement, n a s a l a i r f l o w , TcP02 & TcPC02 were monitored f o r 4-6h pre-Naltrexone. Naltrexone 1-3 mgmlk was given i.v. & monitoring continued f o r 4-6h. Samples f o r B-ED assay were taken p r i o r t o & l h post-Naltrexone, & a l s o from 10 c o n t r o l i n f a n t s weighing 41,700 gms, without apnea o r o t h e r s i g n i f i c a n t pathology (GA 28-35 wks). RESULTS: No drug sidee f f e c t s were detected. G r . A-No i n f a n t showed an improvement i n apnea post-Naltrexone. Gr. B-5 recordings were u n s a t i s f a c t o r y .
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3 i n f a n t s showed no change & 3 i n f a n t s showed more severe apnea post-Naltrexone. No s i g n i f i c a n t d i f f e r e n c e was found i n serum B-endorphin l e v e l s before & a f t e r Naltrexone. B-endorphin l e v e l s were s i g n i f i c a n t l y higher (pL.001) i n i n f a n t s with apnea of prematurity than in c o n t r o l i n f a n t s . B-endorphin l e v e l s d i d n o t change with increasing g e s t a t i o n a l o r p o s t n a t a l age.
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DUE TO MATERNAL, NOT FETAL O R PLACENTAL, METABOLISM.
' 394 David Manchester, Curt Freed, P e t e r Hulac and P e t e r Earl. University of Colorado School of Medicine, University Hospital, Departments of P e d i a t r i c s and Medicine, Denver, 80262.
Clearance of Phenytoin (PH) i n c r e a s e s during pregnancy (Lander e t a l . Eur. J. Clin. Pharm. 1984), but t h e s i t e s of i t s apparent---l y enhanced metabolism and t h e mechanisms responsible a r e unknown. We have observed decreased maternal clearance of PH withi n a few hours of d e l i v e r y suggesting t h a t products of concept i o n e i t h e r p a r t i c i p a t e d i r e c t l y i n metabolism of PH o r s t i m u l a t e maternal systems. To approach t h i s problem, we estimated f e t a l c o n t r i b u t i o n s t o PH metabolism by following disappearance of t r a n s p l a c e n t a l l y acquired drug i n 9 neonates born t o women whose pH requirements had increased during pregnancy and compared g v i t r o metabolism of PH by p l a c e n t a s from t r e a t e d (N=2) and non--t r e a t e d (N=5) women with t h a t of r a t h e p a t i c microsomes.
I n t h e f i r s t 18 t o 24 hours following d e l i v e r y , plasma PH l e v e l s decreased by only 10-50% i n non-breast f e d neonates i n d i c a t i n g t h a t increased clearance of drug during pregnancy could n o t be accounted f o r by f e t a l metabolism. While oxidation of PH was det e c t a b l e i n r e a c t i o n mixtures incubated f o r 30 t o 60 min with r a t l i v e r microsomes, no metabolites could be detected followi n g incubations up t o 14 hours with e i t h e r p l a c e n t a l homogenates o r postmitochondrial supernatants. These r e s u l t s suggest t h a t products of conception do n o t p a r t i c i p a t e s i g n i f i c a n t l y i n PH metabolites during pregnancy. Rather i t appears t h a t a f a c t o r ( s ) produced by t h e f e t a l -p l a c e n t a l u n i t d i r e c t l y s t i m u l a t e s matern a l metabolic pathways.
HEMODYNAMIC CONSEQUENCES OF NITROGLYCERIN INFUSION D U R I N G GROUP B STREPTOCOCCAL SEPSIS I N PIGLETS.
395 William L . Meadow, Brian F. Rudinsk , and % S t r a t e s (Span. by K.S. m~e~t .
of Pediatric:, Univ. o f Chicago Medical Center, Chicago, I L Cardiovascular c o l l a p s e i s a common cause of death in newborn s e p s i s . Vasodilator therapy has recently been suggested to be of s i g n i f i c a n t hemodynamic b e n e f i t in a number of shock s t a t e s . We assessed the e f f e c t s of n i t r o g l y c e r i n ( N G ) , a d i r e c t -a c t i n g smooth muscle r e l a x a n t , on systemic and pulmonary hemodynamics in a p i g l e t model of Group B Streptococcal s e p s i s .
P i g l e t s (n=4) were a n a e s t h e t i z e d , intubated, and v e n t i l a t e d . Systemic blood pressure (BP), pulmonary a r t e r y pressure (PAP), c a r d i a c output (CO), and h e a r t r a t e (HR) were monitored d i r e c t l y and continuously. Sepsis was induced by continuous infusion of serotype Ib Group 8 Streptococci (GBS) @ approximately 5 X 107 organisms/kg/min. Ventricular f i l l i n g pressures were held constant during the e n t i r e experiment by adjustment of i .v. infusion r a t e .
A f t e r 30 minutes of GBS infusion, CO f e l l by 32 t 7% (S.D.), PAP rose by 225 f 97% (both p< 0.01) while BP f e l l by 1 f 6% and HR rose b 4 f 4% (both p = N.S.)
While GBS infusion continued, NG infusion was begun. For NG @ 8 mcg/kg/min and 16 mcg/kg/min respectively, CO f e l l by 7 f 9% ( p = N.S.) and 19 f 11% (p< 0 . 0 1 ) , BP f e l l by 9 f 6% (p< 0.05) and 13 f 4% (p< 0.01), PAP rose by 2 f 9% and 4 f 16% (both p = N.S.).
and HR rose by 7 f 9% ( p = N.S.) and 11 f 6% (p< 0.05). Conclusion: NG infusion during GBS s e p s i s in p i g l e t s had l i t t l e apparent hemodynamic b e n e f i t .
SELECTIVE SYSTEMIC VASOCONSTRICTION WITH PRESERVED CARDIAC OUTPUT D U R I N G GBS-I NDUCED PULMONARY HYPER-
William L . Meadow, Brian F. Rudinsky, and Elene S t r a t e s (span. by K.S. ~e e r . Dept. of Peds, U . of Chicago Med Center, Chicaqo, I L Pharmacologic therapy directed a t s e l e c t i v e l y lowering pulmonary a r t e r y pressure (PAP) in p e r s i s t e n t pulmonary hypertension of t h e newborn (PPHN) has been largely unsuccessful.
As an a l t e r n a t i v e approach, we have modelled PPHN i n s e p t i c p i g l e t s , and achieved s e l e c t i v e elevation of systemic blood pressure (BP) while preserving c a r d i a c o u t p u t (CO). P i g l e t s (n=4) were a n a e s t h e t i z e d , intubated, and v e n t i l a t e d . BP, PAP, and CO were measured d i r e c t l y and continuously. Pulmonary hypertension was induced by intravenous infusion of serotype Ib Group B Streptococci (GBS) @ approximately 5 X 107 organisms/kg/min.
After 30 minutes of GBS infusion, PAP had r i s e n by 225 f 97% (S.D.), CO f e l l by 32 + 7%, (both p < 0 . 0 1 ) and BP f e l l by 1 f 6% ( p = N.S.). While GBS continued, infusions of Nitroglycerin (NG) @ 16 mcg/kg/min plus Epinephrine (EPI) @ 2 mcg/kg/min were begun. A f t e r 1 hour of NG + EPI, BP had r i s e n by 41 + 18% ( p < O . O 1 ) , while PAP f e l l by 3 f 18% and C O f e l l by 1 8 f 24% (both p = N.S.).
Conclusions: 1) PPHN can be modelled by GBS infusion in p i g l e t s . 2) NG + EPI s e l e c t i v e l y elevated BP without r a i s i n g PAP in t h i s model. 3) N G + EPI induced s e l e c t i v e e l e v a t i o n of systemic BP without s i g n i f i c a n t l y decreasing CO. 4) S e l e c t i v e systemic vasoconstriction with preserved CO may be a f e a s i b l e s t r a t e g y f o r human i n f a n t s with PPHN.
